Get the Stockscreener App
1.05
13.93%
-0.17
Pre-market:
1.05
Humacyte Inc stock is traded at $1.05, with a volume of 13.16M.
It is down -13.93% in the last 24 hours and down -10.26% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.22
Open:
$1.25
24h Volume:
13.16M
Relative Volume:
2.52
Market Cap:
$202.65M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-0.9813
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+5.11%
1M Performance:
-10.26%
6M Performance:
-57.66%
1Y Performance:
-74.58%
1-Day Range:
$1.04
$1.29
1-Week Range:
$0.88
$1.29
52-Week Range:
$0.88
$4.14
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.05 | 235.46M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
HUMA Stock Soars Amid Strategic Business Moves and Financial Outlook - StocksToTrade
HUMA Stock Shows Volatility Amid Speculation and Economic Factors - timothysykes.com
Why Humacyte (HUMA) Is Up 19.6% After New DoD Funding For Biologic Vascular Repair - Yahoo Finance
Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist (NASDAQ:HUMA) - Seeking Alpha
Humacyte rises on Department of Defense funding for lab-made blood vessels - TradingView
BTIG reiterates Buy rating on Humacyte stock amid DoD funding news - Investing.com
HUMA Stock Is Soaring Today – Here’s Everything To Know About The DOD Funding Fueling The Surge - Stocktwits
Humacyte says new U.S. law backs bioengineered vessels (HUMA) - Seeking Alpha
Humacyte announces new U.S. Department of Defense funding for procurement of bioengineered blood vessels - marketscreener.com
Humacyte Says US DoD to Provide Funding for Procurement of Bioengineered Blood Vessels; Shares Rise - marketscreener.com
Humacyte Announces New U.S. Department Of Defense Funding For Procurement Of Bioengineered Blood Vessels - TradingView
Humacyte stock jumps after securing DoD funding for vascular repair tech - Investing.com Australia
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge - Asianet Newsable
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels - Yahoo Finance
RSI Check: Can Humacyte Inc sustain its profitabilityJuly 2025 Short Interest & Verified Stock Trade Ideas - baoquankhu1.vn
Humacyte Secures DOD Funding for Bioengineered Blood Vessels - Intellectia AI
Breakouts Watch: Will Humacyte Inc benefit from rising consumer demandMarket Growth Review & High Win Rate Trade Tips - baoquankhu1.vn
Humacyte set to unveil advances in vascular surgery innovation - Traders Union
Macro Review: Will Humacyte Inc benefit from green energy policiesWeekly Loss Report & Weekly High Return Opportunities - baoquankhu1.vn
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Does Humacyte Inc Equity Warrant have declining or rising EPSBuy Signal & Daily Momentum Trading Reports - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Biotechnology Innovator with a 648% Potential Upside - DirectorsTalk Interviews
Is Humacyte Inc. Equity Warrant in a long term uptrendTrade Risk Assessment & Technical Pattern Based Buy Signals - mfd.ru
Is Humacyte Inc. stock forming a triangle patternBull Run & Advanced Swing Trade Entry Plans - Mfd.ru
Aug Retail: Can Humacyte Inc sustain its profitability2025 Stock Rankings & Safe Entry Point Identification - baoquankhu1.vn
Pharma News: What are the analyst revisions for Air T IncIs Humacyte Inc stock a good investment in YEAR2025 Short Interest & Community Verified Swing Trade Signals - baoquankhu1.vn
Smart Money: What is the target price for Humacyte Inc Equity Warrant stockRate Hike & Safe Entry Momentum Tips - baoquankhu1.vn
Rate Cut: What is the target price for Humacyte Inc Equity Warrant stockNew Guidance & Daily Growth Stock Tips - baoquankhu1.vn
Humacyte (HUMA) Valuation Check As Financing And Israel Filing Plans Lift Investor Interest - Sahm
Aug Swings: Whats the fair value of Humacyte Inc Equity Warrant stockJuly 2025 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Stop Loss: Will Humacyte Inc benefit from rising consumer demandRisk Management & Technical Confirmation Trade Alerts - baoquankhu1.vn
Humacyte Ends Sale Agreement with Jefferies LLC - MSN
Humacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Volatility Watch: What are Humacyte Incs technical support levelsTrade Analysis Summary & Community Supported Trade Ideas - baoquankhu1.vn
Humacyte (NASDAQ:HUMA) Given New $10.00 Price Target at Benchmark - MarketBeat
Benchmark lowers Humacyte stock price target to $10 on Israel filing plans - Investing.com India
Humacyte Stock (HUMA) Opinions on Recent Price Surge - Quiver Quantitative
Whale Trades: Whats the fair value of Humacyte Inc stock2025 Price Momentum & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 614% Upside in the Biotech Sector - DirectorsTalk Interviews
Published on: 2026-01-15 08:53:32 - baoquankhu1.vn
Analyst Upgrade: Can Humacyte Inc. stock maintain growth trajectoryTrade Signal Summary & Weekly Momentum Picks - Bộ Nội Vụ
CEO Moves: What catalysts could drive Humacyte Inc. stock higherPortfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Humacyte, Inc. (NASDAQ:HUMA): Are Analysts Optimistic? - Yahoo Finance
Quarterly Risk: Does Humacyte Inc Equity Warrant stock benefit from AI growthPortfolio Return Report & Verified Swing Trading Watchlists - baoquankhu1.vn
While institutions invested in Humacyte, Inc. (NASDAQ:HUMA) benefited from last week's 10% gain, retail investors stood to gain the most - simplywall.st
Wall Street analysts see Humacyte, Inc. (HUMA) as a buy: Should you invest? - MSN
Is Humacyte Inc. Equity Warrant stock undervalued vs historical averagesTrail vs Road Selection & quick comparison of popular models - ulpravda.ru
How buybacks impact Humacyte Inc. Equity Warrant stock valueJuly 2025 Gainers & Entry Point Confirmation Alerts - ulpravda.ru
Will Humacyte Inc. Equity Warrant stock gain from lower inflationPortfolio Gains Report & Fast Gaining Stock Reports - ulpravda.ru
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):